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Abstract 
Follicular lymphomas of germinal center (B- or T-
cell) origin include follicular lymphoma (FL), 
nodular lymphocyte predominant Hodgkin 
lymphoma (NLPHL), and angioimmunoblastic T-
cell lymphoma (AITL).Other lymphomas of 
presumed follicular origin comprise mantle cell 
lymphoma (MCL) and marginal zone lymphoma 
(MZL) (Fig. 1). In this article we describe the 
clinical, pathological and genetic features of 
follicular lymhomas of germinal center (B- or T-cell) 
origin. 
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Identity 
Germinal center (GC)-derived lymphomas include 
follicular lymphoma (FL), nodular lymphocyte 
predominant Hodgkin lymphoma (NLPHL), and 
angioimmunoblastic T-cell lymphoma (AITL). 
Clinics and pathology 
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Figure 1.  Schematic figure of a lymphoid follicle with its "zones" and the related lymphomas. Lymphomas are 
placed on the follicular zones according to the location of the putative normal counterpart of the tumor cells. GC-
derived lymphomas include both B-cell (Follicular lymphoma [FL], nodular lymphocyte predominant Hodgkin 
lymphoma [NLPHL]) and T-cell (angioimmunoblastic T-cell lymphoma [AITL]) lymphomas. 
 
Disease 
Follicular lymphomas of germinal center (GC) (B- 
or T-cell) origin include follicular lymphoma (FL), 
nodular lymphocyte predominant Hodgkin 
lymphoma (NLPHL), and angioimmunoblastic T-
cell lymphoma (AITL) (Fig. 1).Other lymphomas of 
presumed follicular origin that comprise mantle cell 
lymphoma (MCL) andmarginal zone lymphoma 
(MZL) (Fig. 1) are not herein described. Within the 
microenvironment of all the follicular lymphomas of 
GC origin, tumour cells show a topographical and 
functional relationship with follicular dendritic cells 
(FDC), and reactive lymphoid and stromal cells 
(Carbone et al., 2009). The 2008 "WHO 
Classification of Tumours of Haematopoietic and 
Lymphoid Tissues" has addressed the problem of 
early events in the evolution of lymphoid neoplasia 
(Campo et al., 2011). Examples of early lymphoma 
subtypes have been recognized for GC-derived 
lymphomas and include in situ follicular 
neoplasia/early FL (Campo et al., 2011, Carbone and 
Santoro, 2011; Swerdlow et al., 2016), early NLPHL 
(Carbone and Gloghini, 2012) and early AITL 
(Carbone and Gloghini, 2014B; Swerdlow et al., 20.
Pathology 
Follicular lymphomas of germinal center B-cell 
origin.  
- Follicular lymphomas (FL).  FLs are derived from 
GC B cells and maintain the gene expression 
programme of this stage of differentiation. Histology 
of FL may be indolent with small cells (centrocytes) 
or aggressive with larger cells (centroblasts). Unlike 
normal GC B cells, FLs express BCL2, as a result of 
the characteristic t(14;18) translocation, together 
with CD20, CD10 and BCL6. 
In in situ follicular neoplasia the neoplastic cells are 
localized "in the place" that is occupied by the 
normal counterpart of the tumour cell, without 
invasion of surrounding structures (Carbone and 
Santoro, 2011; Carbone and Gloghini, 2014 A). The 
abnormal follicles involved by in situ follicular 
neoplasia have monotonous-appearing GCs 
surrounded by well-preserved mantle zones. The 
intrafollicular BCL2 positive GC B cells are located 
within the meshwork of the CD23+ FDC and 
coexpress CD10, BCL6 and CD20 and are CD3 
negative. The proliferation index rate, as assessed by 
Ki67, is low. The FDC meshwork usually form a 
well-developed "spherical" dendritic meshwork with 
a sharp outline highlighting well-preserved mantle 
zone. Other patterns that can be seen include 
contracted/distorted /disintegrated FDC meshworks. 
As compared with in situ follicular neoplasia, the 
follicles involved by overt FL usually have thinner 
mantle zones and higher proliferation index rate. 
However, they have a similar FDC pattern with a 
well-developed round spherical meshwork. 
- Nodular lymphocyte predominant Hodgkin 
lymphoma (NLPHL).  Tumour cells are derived 
from antigen-selected mutating GC B cells, as 
supported by the expression of BCL6 and CD40, the 
gene expression profile, the presence of CD4+ and 
PD1+ T cells surrounding the tumour cells and the 
presence of a follicular dendritic cell meshwork 
within the tumour nodules. The so-called NLPHL is 
a B-cell lymphoma, with a typical antigen profile 
(Carbone and Gloghini, 2017) (Fig. 2) and an 
indolent clinical behavior (Carbone et al., 2013). 
Interestingly, pathologic and molecular studies have 
shown similarities between NLPHL and T-cell or 
histiocyte-rich large B-cell lymphoma 
(THCRLBCL) (Boudová et al, 2003; Brune et al., 
2008). Other features of NLPHL are reported in the 
specific article/section of the Atlas of Genetics and 
Cytogenetics in Oncology and Haematology. 
Follicular lymphomas of germinal center T-cell 
origin.  
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AITL. AITL is a peripheral T-cell lymphoma 
characterized by a prominent proliferation of high 
endothelial venules. In early lymph-node 
involvement by AITL, the neoplastic T cells 
preferentially occupy the B-cell follicles sometimes 
mimicking a FL of B-cell origin (Carbone and 
Gloghini, 2014 B). AITL tumour cells show the 
phenotype of normal follicular helper T cells. For the 
designation of AITL, the neoplastic cells should 
express at least 2 or 3 TFH-related antigens, 
including CD279/PD1, CD10, BCL6, CXCL13, 
ICOS, SAP, and CCR5 (reviewed in Swerdlow et al, 
2016). Typically, the tumour cells of AITL also 
express CD3 and CD4. The CD4+ tumour cells 
represent a minority of the neoplastic cell 
population, their detection being facilitated by the 
co-expression of CD10. Neoplastic CD4+ T cells of 
AITL are admixed with B cells, eosinophils and 
plasma cells. 
 
Figure 2.  Phenotypic profile of lymphocyte predominant (LP) tumour cells. Abbreviations. GC, germinal center; 
NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; EBV, Epstein Barr virus. 
 
Evolution 
 Progression and transformation 
FL is the most common subtype of indolent 
lymphomas. It is characterized by relapses and 
remissions, usually controlled by Rituximab. On 
clinical progression, whether FL histology remains 
indolent or has become aggressive is an important 
issue: the relevant salvage therapy is selected based 
on histology, and a watchful waiting strategy can be 
adopted if the histology remains indolent (Tomita, 
2017). It has been reported that 30-40% of FL cases 
transform into an aggressive lymphoma (tFL) with a 
poor prognosis (Bouska et al., 2017). An analysis of 
lymphoma cell specimens at histological 
transformation has identified multiple 
transformation-associated abnormalities, such as 
MYC upregulation, TP53 mutation and changes in 
the tumour microenvironment (Kahl and Yang, 
2016). Transformation to aggressive lymphoma is a 
critical event in the clinical course of patients 
affected by FL. Yet, it is a challenge to reliably 
predict transformation at the time of diagnosis. 
However, we are currently lacking a prognostic 
index that would specifically address transformation 
rather than disease progression or overall survival 
(Kridel et al., 2017). 
Regarding NLPHL, clinic and pathologic 
observations have demonstrated that it may evolve 
to a completely diffuse T-cell-rich proliferation 
resembling a THCRLBCL. The 2016 revision of 
WHO classification has recommended the 
designation of these cases as THCRLBCL-like 
transformation of NLPHL (Swerdlow et al., 2016). 
Clinical features of AITL are reported in the specific 
article/section of the Atlas of Genetics and 
Cytogenetics in Oncology and Haematology. 
Genetics 
Note 
The genes most frequently mutated in tFL include 
KMT2D (MLL2), CREBBP, EZH2, BCL2 and 
MEF2B. Many recurrently mutated genes are 
involved in epigenetic regulation, the Janus-
activated kinase-signal transducer and activator of 
transcription (STAT) or the nuclear factor-kb 
pathways, immune surveillance and cell cycle 
regulation (Bouska et al., 2017). 
 
 
Table 1 shows genetic alterations of clinical value in follicular lymphoma (FL) and diffuse large B-cell lymphoma 
(DLBCL), of the GC B-cell origin type). 
Disease subtype Genes Normal function Technology used to detect Genotype-directed therapy 
FL/GCB DLBCL BCL2 Antiapoptotic FISH Venetoclax 
  KMT2D/MLL2 H3K4 methyltransferase Sequencing   
  CREBBP Histone acetyltransferase Sequencing Trials of HDAC inhibitors 
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  EP300 Histone acetyltransferase Sequencing   
  EZH2 H3K27 methyltransferase Sequencing Trials of EZH2 inhibitors 
  MEF2B Transcription factor Sequencing   
Modified and adapted from Taylor et al., (2017)
 
Genetic features of NLPHL are reported in the 
specific article/section of the Atlas of Genetics and 
Cytogenetics in Oncology and Haematology. 
 
Recurrent genetic abnormalities in AITL include 
TET2, IDH2, DNMT3A, RHOA, and CD28 
mutations, as well as gene fusions such as ITK/SYK 
or CTLA4 / CD28 (Leclaire Alirkilicarslan et al., 
2017). All these abnormalities have a role in the 
process of lymphomagenesis and may represent the  
 
target of tailored therapies (reviewed in Swerlow et 
al., 2016). 
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